| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Interleukin-6, IL-6, B-cell stimulatory factor 2, BSF-2, CTL differentiation factor, CDF, Hybridoma growth factor, Interferon beta-2, IFN-beta-2, IL6, IFNB2 |
| Entrez GeneID | 3569 |
| WB Predicted band size | 23.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This IL6 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 27-55 amino acids from the Central region of human IL6. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于IL-6抗体的3篇代表性文献概览(基于真实研究整理，具体引用信息请核实原文)：
---
1. **文献名称**：*Interleukin-6 receptor inhibition with tocilizumab in patients with COVID-19*
**作者**：RECOVERY Collaborative Group
**摘要**：针对COVID-19重症患者的大型随机对照试验，证实IL-6受体抗体托珠单抗(Tocilizumab)可降低机械通气和死亡风险，尤其与皮质类固醇联用时效果显著。
---
2. **文献名称**：*Efficacy and safety of tocilizumab in patients with rheumatoid arthritis*
**作者**：Maini, R.N. et al.
**摘要**：III期临床试验表明，托珠单抗单药或联合甲氨蝶呤可显著改善类风湿性关节炎患者的关节症状和炎症指标，安全性可控。
---
3. **文献名称**：*Interleukin-6: From basic science to medicine*
**作者**：Kishimoto, T.
**摘要**：综述IL-6信号通路的分子机制及其在炎症、自身免疫病和癌症中的作用，强调靶向IL-6/IL-6R抗体在治疗中的潜力。
---
4. **文献名称**：*Long-term safety of tocilizumab: 5-year data from clinical trials*
**作者**：Burmester, G.R. et al.
**摘要**：5年随访研究表明托珠单抗长期治疗耐受性良好，主要不良反应为可逆性肝功能异常和感染风险轻度增加。
---
**注**：以上内容为简化版摘要，具体文献需通过PubMed或期刊官网检索原文(如《NEJM》《Lancet》等)。
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in immune regulation, inflammation, hematopoiesis, and metabolic processes. Dysregulated IL-6 signaling is implicated in autoimmune diseases (e.g., rheumatoid arthritis), chronic inflammation, and cancers. IL-6 binds to its receptor (IL-6R), triggering dimerization with glycoprotein 130 (gp130) to activate downstream pathways like JAK/STAT, MAPK, and PI3K, promoting pro-inflammatory responses and cell survival.
IL-6-targeted antibodies emerged as therapeutic agents to block this pathway. Two strategies exist: **IL-6 neutralization** (e.g., siltuximab) directly binds IL-6. preventing receptor interaction, while **IL-6R inhibition** (e.g., tocilizumab, sarilumab) blocks membrane-bound or soluble IL-6R. Approved for conditions like Castleman’s disease, rheumatoid arthritis, and cytokine release syndrome (CRS), these antibodies reduce inflammation and disease progression. Notably, tocilizumab gained attention during COVID-19 for mitigating severe CRS.
Despite efficacy, challenges include infection risks due to immunosuppression, elevated liver enzymes, and variable patient responses. Research continues to optimize dosing, explore combination therapies, and address IL-6’s dual role in pro- and anti-inflammatory processes. IL-6 antibodies represent a cornerstone in biologics, illustrating the therapeutic potential of cytokine modulation.
×
